摘要
前蛋白转化酶枯草溶菌素9(proprotein convertase subtilisin/kexin type 9,PCSK9)是一种由肝细胞合成和分泌的蛋白质,其可通过促进肝细胞表面低密度脂蛋白受体(LDLR)降解来减少LDL内化和清除。随着PCSK9抑制剂的逐步推广和使用,越来越多研究者发现PCSK9可以调控动脉粥样硬化形成、血小板活化和血栓形成、炎症反应以及糖脂代谢,而这些均为经皮冠状动脉介入治疗(percutaneous coronary intervention, PCI)术后支架内再狭窄(in-stent restenosis, ISR)的主要诱因。该文就PCSK9在ISR中的作用机制研究进展进行综述,并对其作为冠心病药物治疗靶点的应用作初步展望。
Proprotein convertase subtilisin/kexin type 9(PCSK9)is a protein that is synthesized and secreted from hepato-cytes.It can reduce low-density lipoprotein(LDL)uptake by promoting degradation of LDL receptor(LDLR)on the surface of hepatocyte.Since application of PCSK9 inhibitors become more common,researchers have found that PCSK9 can regulate ather-osclerosis development,platelet activation and thrombosis,inflammation,and glycolipid metabolism.PCSK9 is also the main in-ducements of in-stent restenosis(ISR)after percutaneous coronary intervention(PCI).Therefore,this article reviews the research progress of mechanism of PCSK9 in ISR after PCI,and makes a preliminary prospect on the application of PCSK9 as a therapeu-tic target in coronary atherosclerotic heart disease.
作者
易子渝
朱国富
Yi Ziyu;Zhu Guofu(The Postgraduate School,Kunming Medical University,Kunming 650500,China;Department of Cardiology,the Second Af filiated Hospital of Kunming Medical University,Kunming 650101,China)
出处
《华中科技大学学报（医学版）》
CAS
CSCD
北大核心
2024年第3期403-408,共6页
Acta Medicinae Universitatis Scientiae et Technologiae Huazhong
基金
云南省卫生健康委医学后备人才培养计划资助项目(No.H-2018033)。
